- Home
- VSTM vs LXEO Comparison
VSTM vs LXEO Comparison
Compare VSTM & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VSTM | LXEO |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.8M | 731.3M |
| IPO Year | 2012 | 2023 |
Fundamental Metrics
Financial Performance| Metric | VSTM | LXEO |
|---|---|---|
| Price | $6.16 | $7.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $13.38 | ★ $18.60 |
| AVG Volume (30 Days) | ★ 2.0M | 1.3M |
| Earning Date | 03-19-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,379,000.00 | N/A |
| Revenue This Year | $208.54 | N/A |
| Revenue Next Year | $251.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 33.79 | N/A |
| 52 Week Low | $4.01 | $1.45 |
| 52 Week High | $11.25 | $10.99 |
Technical Indicators
Market Signals| Indicator | VSTM | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 35.18 | 38.11 |
| Support Level | $6.14 | $7.24 |
| Resistance Level | $6.53 | $7.75 |
| Average True Range (ATR) | 0.48 | 0.74 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 3.12 | 13.77 |
Price Performance
Historical ComparisonAbout VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.